Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as high-dose Group ACYW135X Meningococcal Conjugate Vaccine
Group ACYW135X Meningococcal Conjugate Vaccine · 1 trial · 1 indication
The incidence rates of adverse reactions 30 days after vaccination
| Arm | Type | Description |
|---|---|---|
| high-dose experimental group | EXPERIMENTAL | 2\~59 years old |
| medium-dose experimental group | EXPERIMENTAL | 2\~59 years old |
| low-dose experimental group | EXPERIMENTAL | 2\~6 years old |
| placebo group | PLACEBO_COMPARATOR | 2\~6 years old |
| active control group | ACTIVE_COMPARATOR | 2\~3 years old |
| Name | Type | Description |
|---|---|---|
| high-dose Group ACYW135X Meningococcal Conjugate Vaccine | BIOLOGICAL | high-dose Group ACYW135X Meningococcal Conjugate Vaccine |
| medium-dose Group ACYW135X Meningococcal Conjugate Vaccine | BIOLOGICAL | medium-dose Group ACYW135X Meningococcal Conjugate Vaccine |
| low-dose Group ACYW135X Meningococcal Conjugate Vaccine | BIOLOGICAL | low-dose Group ACYW135X Meningococcal Conjugate Vaccine |
| Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) | BIOLOGICAL | Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) |
| Placebo | BIOLOGICAL | placebo |
Inclusion Criteria: * Healthy participants aged 2 to 59 years; * The participant and/or their legal guardian can understand and voluntarily sign the informed consent form (for participants aged 8 to 17 years, the form must be signed jointly by the participant and their legal guardian); * Be willing...
Group ACYW135X Meningococcal Conjugate Vaccine is an investigational vaccine developed by Sinovac Biotech, Ltd for the prevention of meningococcal meningitis, an infectious disease. It is designed as a conjugate vaccine covering meningococcal groups A, C, Y, W135, and X, and is being studied in a Phase 1 clinical program.
Group ACYW135X Meningococcal Conjugate Vaccine is being developed for meningococcal meningitis, an infectious disease of the membranes surrounding the brain and spinal cord. The Phase 1 trial enrolls healthy volunteers from 2 years of age, reflecting a preventive vaccine intended for use in broad age groups.
Sinovac Biotech, Ltd develops Group ACYW135X Meningococcal Conjugate Vaccine. Sinovac trades under the ticker SVA. The company is the sponsor of the vaccine's Phase 1 clinical program in meningococcal meningitis.
Group ACYW135X Meningococcal Conjugate Vaccine is in Phase 1 development. It is an investigational vaccine and has not completed clinical development. The Phase 1 program consists of one trial that is not yet recruiting, with no completed trials reported for this asset.
Group ACYW135X Meningococcal Conjugate Vaccine is being studied in one Phase 1 trial, NCT07374510, titled Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine. The trial targets meningococcal meningitis, is not yet recruiting, and plans to enroll 150 healthy volunteers aged 2 years and older.
The Phase 1 trial NCT07374510 is a randomized, double-blind, placebo-controlled study of Group ACYW135X Meningococcal Conjugate Vaccine. It plans to enroll 150 healthy volunteers of all sexes, aged 2 years and older, in the meningococcal meningitis indication. The trial is not yet recruiting.
Yes. High-dose Group ACYW135X Meningococcal Conjugate Vaccine is another name used for Group ACYW135X Meningococcal Conjugate Vaccine, the Sinovac Biotech vaccine in Phase 1 development for meningococcal meningitis. Both names refer to the same investigational asset studied in trial NCT07374510.